Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | AKR1B1 | P15121 | 5/20 | 0.68 |
| ▸ | PIM1 | P11309 | 9/20 | 0.65 |
| ▸ | PIM2 | Q9P1W9 | 9/20 | 0.65 |
| ▸ | CISD1 | Q9NZ45 | 3/20 | 0.63 |
| ▸ | MAOA | P21397 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.63 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.62 |
| ▸ | GSK3B | P49841 | 2/20 | 0.59 |
| ▸ | TTR | P02766 | 1/20 | 0.59 |
| ▸ | IGF1R | P08069 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2626932 | 0.86 | NAT1 (0.69) | PIM1CISD1GSK3BRAB9A | |
| SCHEMBL7465302 | 0.86 | PIM1 (0.73) | HPGDAKR1B1PIM1PIM2CISD1 | |
| SCHEMBL7465304 | 0.86 | PIM1 (0.73) | HPGDAKR1B1PIM1PIM2CISD1 | |
| SCHEMBL12107430 | 0.85 | HPGD (1.00) | HPGDAKR1B1PIM1PIM2CISD1 | |
| SCHEMBL12259747 | 0.81 | AKR1B1 (1.00) | HPGDAKR1B1PIM1PIM2CISD1 | |
| SCHEMBL1250348 | 0.79 | PIM1 (1.00) | AKR1B1PIM1PIM2CISD1MAOA | |
| SCHEMBL2548389 | 0.79 | PIM1 (1.00) | AKR1B1PIM1PIM2CISD1MAOA | |
| SCHEMBL1250346 | 0.79 | PIM1 (1.00) | AKR1B1PIM1PIM2CISD1MAOA | |
| SCHEMBL1250387 | 0.78 | PIM1 (1.00) | HPGDAKR1B1PIM1PIM2CISD1 | |
| SCHEMBL2132747 | 0.78 | PIM1 (1.00) | HPGDAKR1B1PIM1PIM2CISD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9518285-B2 | Chemiluminescent compositions, methods, assays and kits for oxidative enzymes | Life Technologies Corporation (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150284766-A1 | CHEMILUMINESCENT COMPOSITIONS, METHODS, ASSAYS AND KITS FOR OXIDATIVE ENZYMES | Life Technologies Corporation | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284766-A1 | CHEMILUMINESCENT COMPOSITIONS, METHODS, ASSAYS AND KITS FOR OXIDATIVE ENZYMES | AOX1, CAT, LPO | HPGD 266/4885AKR1B1 77/4885PIM1 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.